PF-05089771
Phase 2Small molecule
PfizerPF-05089771 is one of 72 small molecule programs targeting Arthritis. It is currently in Phase 2.
2
Indications
13
Total Trials
0
Active Trials
71
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
187 competitors in Peripheral Neuropathy
#DrugCompanyPhaseTrials
1Journavx
Vertex PharmaceuticalsPhase 3
Namenda
AbbViePhase 3
Farxiga
AstraZenecaPhase 3
Nucynta
CCollegium Pharmaceutical, Inc.
Phase 3
Ixempra
RR-Pharm
Phase 3
Aspercreme Warming
AAveritas Pharma, Inc.
Phase 3
Lamictal
GGlaxo Dba Glaxosmithkline
Phase 3
Epsom Salt
FFresenius Kabi Oncology Ltd.
Phase 3
Oxycontin
PProtega
Phase 3
Calcium Gluconate
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Oral3 trials
Single Dose1 trial
TED1 trial
6 more indications
Efficacy and Safety1 trial
Pain Perception1 trial
Concentration1 trial
Peripheral Neuropathy1 trial
Pregabalin1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for PF-05089771. EMBL-EBI & Wellcome Sanger Institute.
- [4]